Jonathan Riess
Hematology & Oncology · Sacramento, CANPI 1619132461
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $138,287 of the $158,430 with a category attached, or 87.3%. It is spread thinly across 35 manufacturers, the largest accounting for just 11.5%. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $856.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- AstraZeneca$15K
- Regeneron$14K
- Regeneron Healthcare Solutions, Inc.$10K
- E.r. Squibb & Sons, L.L.C.$9K
- Bristol Myers Squibb$8K
- plus $84K from 29 others
Across 224 payments — averaging $43,226 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$4.1M
- AstraZeneca$1.6M
- Merck$1.4M
- Novartis$644K
- Boehringer Ingelheim Pharma GmbH & Co.kg$535K
- Boehringer Ingelheim$489K
- plus $936K from 6 others
What the payments were for
- Consulting fees$138,28787%
- Speaking & faculty fees$7,2615%
- Travel & lodging$7,0604%
- Food & beverage$5,8044%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $18,204 |
| AstraZeneca | 35 | $15,119 |
| Regeneron | 17 | $14,043 |
| Regeneron Healthcare Solutions, Inc. | 13 | $9,985 |
| E.r. Squibb & Sons, L.L.C. | 4 | $8,638 |
| Bristol Myers Squibb | 7 | $8,463 |
| Sanofi | 4 | $7,484 |
| Janssen Scientific Affairs, LLC | 7 | $6,625 |
| Taiho Oncology, Inc. | 8 | $6,594 |
| Novartis | 5 | $5,570 |
| Eli Lilly | 2 | $5,200 |
| Astrazeneca UK Limited | 15 | $4,377 |
| Genentech USA, Inc. | 6 | $4,033 |
| EMD Serono, Inc. | 3 | $3,940 |
| Pfizer | 7 | $3,621 |
| Boehringer Ingelheim | 4 | $3,578 |
| Bayer | 1 | $3,493 |
| Johnson & Johnson | 3 | $3,432 |
| Daiichi Sankyo Inc. | 4 | $3,214 |
| GSK | 2 | $3,200 |
| Seagen Inc. | 1 | $2,750 |
| Blueprint Medicines Corporation | 2 | $2,613 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,250 |
| Amgen | 2 | $2,058 |
| Jazz Pharmaceuticals Inc. | 1 | $1,920 |
| Mirati Therapeutics, Inc. | 3 | $1,665 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,663 |
| Array Biopharma Inc | 2 | $1,541 |
| Novocure Inc. | 2 | $1,185 |
| Beigene, Ltd. | 1 | $888 |
| Ipsen Innovation | 1 | $870 |
| Coherus Oncology, Inc. | 1 | $94 |
| Eisai Inc. | 1 | $72 |
| Astrazeneca AB | 1 | $37 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$158,430 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 105 | $1,701,048 |
| AlecensaAlectinib Hcl | 53 | $1,022,816 |
| RetevmoSelpercatinib | 27 | $389,155 |
| XalkoriCrizotinib | 11 | $185,960 |
| Erlotinib Hcl | 30 | $10,705 |
| XareltoRivaroxaban | 14 | $7,739 |
| Prochlorperazine Maleate | 42 | $526 |
| Mirtazapine | 11 | $379 |
| Dexamethasone | 47 | $262 |
| Ondansetron Hcl | 35 | $178 |
| Olanzapine | 18 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $15,119 | $1,701,048105 claims |
| Genentech USA, Inc.Alecensa | $4,033 | $1,022,81653 claims |
| PfizerXalkori | $3,621 | $185,96011 claims |
| Johnson & JohnsonXarelto | $3,432 | $7,73914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Mehrdad AbediSacramento$613K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.